Ivabradina Teva Group

Ivabradine, the active ingredient in Ivabradina Teva Group, is an If channel inhibitor presented as an oral tablet for systemic use. It selectively lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Teva Group as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards, is manufactured under GMP conditions, and our distribution network ensures timely delivery across multiple continents.

Ivabradine is used in cardiovascular conditions that involve elevated heart rate.

- Chronic stable angina: reduces the frequency of angina attacks by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisation rates. - Ischemic heart disease (coronary artery disease): helps control heart rate to lessen myocardial workload.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Phosphenes (luminous visual phenomena) - Bradycardia (slow heart rate) - Headache - Dizziness - Fatigue - Nausea

Serious or Rare Side Effects: - Severe bradycardia leading to syncope - Atrioventricular block - Worsening heart failure - Visual impairment (persistent disturbances) - Angioedema

Before initiating therapy, clinicians should consider several safety aspects.

- Heart‑rate monitoring: check resting heart rate and discontinue if it falls below 50 bpm. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Concomitant bradycardic agents: avoid combining with beta‑blockers or digoxin without close supervision. - Sick‑sinus syndrome or AV‑block: contraindicated in patients with these rhythm disorders. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Other bradycardic agents (beta‑blockers, digoxin, verapamil): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Verapamil or diltiazem: may modestly raise ivabradine levels. - Quinidine: can increase plasma concentrations. - Amiodarone: may enhance bradycardic effect, requiring heart‑rate monitoring.